Satiety

Satiety

Satiety is the state of feeling full and satisfied after eating, which naturally suppresses the desire for further food intake until the next meal. It is distinct from satiation, which refers to the process of becoming full during a meal. Satiety is governed by a complex network of hormonal, neural, and mechanical signals. Gut hormones such as GLP-1, peptide YY, and cholecystokinin are released in response to nutrient ingestion and act on receptors in the brainstem and hypothalamus to inhibit appetite. Mechanical distension of the stomach activates vagal afferent nerve fibers that relay fullness signals to the brain. Together, these pathways determine how long an individual remains satisfied between meals.

Impaired satiety signaling is a key factor in the pathophysiology of obesity. In individuals with obesity, the hormonal and neural mechanisms that normally regulate food intake may be disrupted, leading to reduced sensitivity to satiety signals and increased caloric consumption. This dysregulation can involve reduced postprandial secretion of satiety hormones, diminished central nervous system responsiveness to these signals, or both. Restoring effective satiety signaling is therefore a major therapeutic strategy in obesity treatment.

Retatrutide enhances satiety through multiple mechanisms inherent to its triple agonist design. The GLP-1 receptor agonist component acts on appetite centers in the brain to promote feelings of fullness, while also slowing gastric emptying to prolong mechanical stomach distension after meals. The GIP receptor activity may further contribute to central appetite regulation. Together, these effects result in a substantial reduction in caloric intake, which is the primary driver of the significant weight loss observed in clinical trials. Participants in retatrutide studies have reported meaningful decreases in hunger and food cravings, consistent with enhanced satiety signaling.